38 million shares become available for sale Monday- that's far more than the 23 million shares sold in the IPO.
Currently at + $5.61 over the IPO price of $20, profit taking likely to ensue- especially since Go Daddy's losses are widening and is deeply in debt in a low threshold business.
On the contrary, sequencing- while noble work, is far from lucrative. PacBio (PACB) is consistently unprofitable.
Their just announced ititeration is still too expensive- uncompetitive in the marketplace.
Company has just gone dark on reporting machines sold- not a good sign.
This a low PPS play for "players" and will end badly- always does.
Illumina is catching most of the profit that's out there. PacBio and the dozens of sequencing companies are no Illumina.
Saying Roche is "desperately.." is hype.
This is a low PPS play that "players" jump on every PR. If you have any insight, you know that.
No, still not a overly lucrative field- yet. Guessing about 1.5B divided by MANY.
Best can be said is it is growing. But we're talking about NOW. A PPS up 68% on a modest PR from a company consistently losing money and widening is beyond a natural reaction- it's a low PPS walk-up by stock market crooks, several I recognize.
I call these "low self-esteem" plays- manipulators,and those that embarrassingly ride their coattails,who have identified ways to jigger things for ill gained profits. Done by those who lack good trading skills.
Just look at the chart- every one of these walk-ups sell off.
SEC should investigate this, INO and other low PPS bios in the hands of the manipulator gang thrown off ST.
You can have the last word as I don't wish to further converse with those trying to rationalize an obvious BS play.
Thomson Reuters/Verus upgrades SYSOREX GLOBAL HOLDINGS CORPORATION from HOLD to BUY.
BY Investars Analyst Actions - public— 11:05 AM ET 10/05/2015
On October 5, 2015 Thomson Reuters/Verus upgraded SYSOREX GLOBAL HOLDINGS CORPORATION (SYRX) from HOLD to BUY.
LOL! A Market Cap of 1.6B for a company with a niche product selling 10-15 machines a year.
That's the last installment from Roche- then it's dilution as PACB has chronic negative cash flow.
The only question is when is this walk-up going to dump.
Analyst Actions: Sysorex Global Holdings Initiated With Buy And $2.50 Price Target At B. Riley
BY Midnight Trader — 8:49 AM ET 10/05/2015
08:49 AM EDT, 10/05/2015 (MT Newswires) -- Sysorex Global Holdings ( SYRX ) shares were initiated by B. Riley with a buy rating and $2.50 price target.
For nubes, the "conversations" here are staged, possibly even the same person. "They" had these leading "conversations" on INO, too- another low priced bio these crooks worked.
Sentiment: Strong Sell
Yes- lot of people shorting this.
Haven't looked to see if there is a shelf but betting dilution, also.
ILMN is the runaway leader in sequencing. PACB is a niche player, to date selling mostly to research institutions, a narrow market.
PACB sells only about a dozen machines a year.
PACB latest iteration still is MUCH more expensive than ILMN.
PACB will have to dilute with more shares when the last small payment from Roche comes in this quarter
PACB is a highly manipulated stock, so much so Jim Cramer warned in the past not to chase it.